Abstract |
The efficacy of long-term, high dose interferon-alpha (IFN-alpha) therapy was studied in seven patients with HTLV-I-associated myelopathy (HAM)/ tropical spastic paraparesis (TSP). IFN-alpha was administered at a dose of 6 x 10(6) international units daily for the initial 2 weeks and thereafter 3 times a week for the following 22 weeks. Five patients showed a sustained improvement in motor performance during and up to 6 months after the completion of IFN-alpha. The other patient who responded to IFN-alpha initially dropped out at 3 months because of depression, while another patient first deteriorated and thereafter dropped out. In the six responders, the absolute number of peripheral blood lymphocytes (PBL) harboring the HTLV-I genome as evaluated by the quantitative polymerase chain reaction method decreased significantly during the therapy period (28.6 +/- 16.6% reduction, P = 0.0083), whereas the one deteriorated patient showed a 2.5-fold increase in HTLV-I-infected cells. The autoproliferation of CD4+ T clone cells from a single cell culture was markedly depressed even after the cessation of IFN-alpha in the responders who completed long-term IFN-alpha therapy. In addition, the CD8+DR+ T cells in the peripheral blood and soluble IL-2 receptor levels in the sera increased significantly during the therapy in all patients (P = 0.0431 and P = 0.0041, respectively). Therefore, the results of our study suggested that both the reduction of HTLV-I proviral DNA load and immunomodulation by long-term IFN-alpha therapy contributed to its sustained clinical benefits.
|
Authors | K Yamasaki, J Kira, Y Koyanagi, Y Kawano, N Miyano-Kurosaki, M Nakamura, E Baba, J Suzuki, A Yamamoto, N Yamamoto, T Kobayashi |
Journal | Journal of the neurological sciences
(J Neurol Sci)
Vol. 147
Issue 2
Pg. 135-44
(Apr 15 1997)
ISSN: 0022-510X [Print] Netherlands |
PMID | 9106118
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- DNA, Viral
- Interferon-alpha
- Receptors, Interleukin-2
|
Topics |
- Adult
- Aged
- Cell Division
(drug effects, immunology)
- DNA, Viral
(analysis)
- Female
- Human T-lymphotropic virus 1
(genetics, immunology)
- Humans
- Interferon-alpha
(administration & dosage)
- Lymphocyte Subsets
(cytology, drug effects, immunology)
- Male
- Middle Aged
- Paraparesis, Tropical Spastic
(drug therapy, immunology, virology)
- Pilot Projects
- Receptors, Interleukin-2
(blood, immunology)
|